Esperion Therapeutics (ESPR) Common Equity (2012 - 2026)
Esperion Therapeutics (ESPR) posted Common Equity of -$307.9 million for Q1 2026, down 1.98% on a QoQ basis from -$302.0 million in Q4 2025, and up 27.75% year-over-year from -$241.0 million in Q1 2025.
Esperion Therapeutics (ESPR) Common Equity (2012 - 2026) Analysis & Trends
Esperion Therapeutics' Common Equity history runs 15 years deep, the most recent figure standing at -$307.9 million for Q1 2026.
- Quarterly Common Equity rose 27.75% year-over-year to -$307.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$307.9 million (up 27.75% YoY) and the FY2025 annual result came in at -$302.0 million, up 22.32% from the prior year.
- Common Equity was -$307.9 million for Q1 2026 at Esperion Therapeutics, down from -$302.0 million in the prior quarter.
- Across five years, Common Equity topped out at -$249.0 million in Q1 2022 and bottomed at -$455.0 million in Q4 2023.
- A 5-year average of -$355.5 million and a median of -$344.2 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity sank 64.4% — and 2026, when it grew 27.75%.
- Esperion Therapeutics' Common Equity stood at -$323.8 million in 2022, then plunged by 40.53% to -$455.0 million in 2023, then gained by 14.57% to -$388.7 million in 2024, then rose by 22.32% to -$302.0 million in 2025, then retreated by 1.98% to -$307.9 million in 2026.
- Business Quant data shows ESPR's Common Equity at -$307.9 million in Q1 2026, -$302.0 million in Q4 2025, and -$451.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | -307.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -307.93 Mn |
| Dec 31, 2025 | -301.97 Mn |
| Sep 30, 2025 | -451.36 Mn |
| Jun 30, 2025 | -433.51 Mn |
| Mar 31, 2025 | -426.21 Mn |
| Dec 31, 2024 | -388.72 Mn |
| Sep 30, 2024 | -370.21 Mn |
| Jun 30, 2024 | -344.22 Mn |
| Mar 31, 2024 | -294.30 Mn |
| Dec 31, 2023 | -454.99 Mn |
| Sep 30, 2023 | -410.00 Mn |
| Jun 30, 2023 | -371.98 Mn |
| Mar 31, 2023 | -329.66 Mn |
| Dec 31, 2022 | -323.78 Mn |
| Sep 30, 2022 | -294.10 Mn |
| Jun 30, 2022 | -291.70 Mn |
| Mar 31, 2022 | -249.04 Mn |
| Dec 31, 2021 | -196.94 Mn |
| Sep 30, 2021 | -362.71 Mn |
| Jun 30, 2021 | -304.31 Mn |